Bosentan
CAS: 147536-97-8
Ref. TM-T6264
10mg | 38.00 € | ||
25mg | 55.00 € | ||
50mg | 80.00 € | ||
100mg | 124.00 € | ||
200mg | 202.00 € | ||
500mg | 304.00 € | ||
1ml*10 (DMSO) | 87.00 € |
Product Information
- Actelion, Ro 47-0203, Benzenesulfonamide
- 4-(1,1-Dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2′-bipyrimidin]-4-yl]benzenesulfonamide
- 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
- Act 434964
- Actelion
- Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2′-bipyrimidin]-4-yl]-
- N-[6-(2-Hydroxyethoxy)-5-(2-Methoxyphenoxy)-2-Pyrimidin-2-Yl-Pyrimidin-4-Yl]-4-Tert-Butyl-Benzenesulfonamide
- Ro 47-0203
- Ro 47-0203/039
- Tracleer
- See more synonyms
- p-tert-Butyl-N-[6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
Bosentan (Benzenesulfonamide) is a sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan decreases both pulmonary and systemic vascular resistance and is particularly used in the treatment of pulmonary arterial hypertension.
Chemical properties
Technical inquiry about: TM-T6264 Bosentan
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.